Medtronic to launch smartphone-enabled continuous glucose monitor; Zyga raises $10M;

@FierceMedDev: NIH launches study of 'exceptional responders' to cancer therapies. Article | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Titan Pharma trial of implant for addicts on track. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: 3-D printed blood vessels? Check. On to the 3-D printed kidneys, say researchers at Harvard. More from MIT Technology Review | Follow @EmilyWFierce

> Medtronic ($MDT) plans to launch a smartphone-enabled continuous glucose monitor, the medical device giant said at the Health 2.0 conference in Santa Clara, CA, this week. It plans to start a pivotal clinical trial of the system this fall. Story

> Zyga Technology raised $10 million to start marketing and further study its minimally invasive spinal surgery products. Of this, Silicon Valley Bank is providing $8 million in debt, while existing investors including Versant Ventures, Split Rock Partners, Domain Associates and MB Venture Partners are offering $2 million in equity. Release

> Liver disease device company Vital Therapies has filed to raise up to $46 million in a follow-on offering. It expects to use the funds to get Phase III data for its ELAD System, an external, allogeneic cellular therapy device that incorporates human liver-derived cells. Filing

> Wireless continuous glucose monitoring company Echo Therapeutics ($ECTE) will suspend operations because it was unable to raise financing. Release

Biotech News

@FierceBiotech: VentiRx banks $50M as it ramps up immuno-oncology research efforts in Seattle. Report | Follow @FierceBiotech

@JohnCFierce: Adaptimmune gathers $104M to fuel hot immuno-oncology tech race - TCRs/CAR-T. More | Follow @JohnCFierce

@DamianFierce: Here's the official Kadmon release on the Waksal swap, replete with semi-acknowledgement of IPO plot. Release | Follow @DamianFierce

@EmilyMFierce: This on misses the mark in so many ways and lacks a basic understanding of drug development. Article | Follow @EmilyMFierce

> Alzheimer's biotech Probiodrug plots a Euro IPO amid a continental boomlet. News

> Valeant talks up the billion-dollar potential of its Phase III eye drug. Story

> Novartis' blockbuster hopeful scores a win in psoriatic arthritis. Article

Pharma News

@FiercePharma: ICYMI yesterday: Overseas limits on J&J's Olysio use might signal trouble back home. Item | More | Follow @FiercePharma

@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

> Pfizer preps its case for FDA pulling Chantix's black-box warning. Article

> Hail GSK's chairman-to-be Philip Hampton: It's a tough job ahead. Item

> Hey, Big Pharma: When the feds swoop in, be nice. It worked for Shire. More

Vaccines News

> Inovio joins Ebola fight while WHO says a vaccine could be ready by year's end. Story

> CureVac inks lung cancer vaccine deal with Boehringer for up to $600M. Report

> U.K. panel under pressure to extend use of Merck's Gardasil to boys. Article

> Pharmacies continue push to lower barriers to seasonal flu vaccination. Report

> Accidental poliovirus dump adds to GSK's production woes. More

Pharma Manufacturing News

> IGI jumps into sterile injectable biz with $9.5M deal with AstraZeneca. More

> Report: 'Green' manufacturing needed to save money as well as the environment. Item

> Sanofi expands production at Merial plant in Brazil. More

> Alkermes manufacturing technology key to Acorda buyout of Civitas. Article

> Impax settles securities suit tied to its manufacturing issues. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.